Infliximab partially impairs the anti‐Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin‐test

Background  Infliximab and etarnecept are now widely used for treating severe psoriasis. However, these drugs, especially infliximab, increased the risk of tuberculosis reactivation. Surprisingly, epidemiological data suggest that the tuberculosis rate in patients taking infliximab in São Paulo State, Brazil, is similar to that of some developed, non‐endemic countries.

[1]  R. Romiti,et al.  Decrease in Mycobacterium tuberculosis specific immune responses in patients with untreated psoriasis living in a tuberculosis endemic area , 2010, Archives of Dermatological Research.

[2]  I. Orme,et al.  Phenotypic Definition of Effector and Memory T-Lymphocyte Subsets in Mice Chronically Infected with Mycobacterium tuberculosis , 2010, Clinical and Vaccine Immunology.

[3]  D Emilie,et al.  Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. , 2009, Arthritis and rheumatism.

[4]  P. Andersen,et al.  Tuberculosis Subunit Vaccination Provides Long-Term Protective Immunity Characterized by Multifunctional CD4 Memory T Cells1 , 2009, The Journal of Immunology.

[5]  C. Antoni,et al.  Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans. , 2009, The Journal of clinical investigation.

[6]  J. Keane,et al.  Tumor necrosis factor blockers influence macrophage responses to Mycobacterium tuberculosis. , 2008, The Journal of infectious diseases.

[7]  G. G. Silveira,et al.  Deficient in vitro anti-mycobacterial immunity despite successful long-term highly active antiretroviral therapy in HIV-infected patients with past history of tuberculosis infection or disease. , 2007, Clinical immunology.

[8]  R. Wallis.  Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. , 2007, The journal of investigative dermatology. Symposium proceedings.

[9]  B. Ryffel,et al.  Tumor necrosis factor is critical to control tuberculosis infection. , 2007, Microbes and infection.

[10]  L. Settas,et al.  Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. , 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[11]  R. Wallis,et al.  Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. , 2006, The Journal of infectious diseases.

[12]  M. Humbert,et al.  Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists , 2006, Arthritis research & therapy.

[13]  R. Joshi,et al.  Persistently elevated T cell interferon-γ responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report , 2006, Journal of occupational medicine and toxicology.

[14]  E. Acevedo-Vásquez,et al.  Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis , 2005, Annals of the rheumatic diseases.

[15]  M. Broder,et al.  Reactivation of latent granulomatous infections by infliximab. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Alan D. Roberts,et al.  Differential contributions of central and effector memory T cells to recall responses , 2005, The Journal of experimental medicine.

[17]  J. Gómez-Reino,et al.  Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. , 2005, Arthritis and rheumatism.

[18]  Lucilaine Ferrazoli,et al.  Micobactérias não-tuberculosas: diversidade das espécies no estado de São Paulo , 2005 .

[19]  E. Agger,et al.  The Influence of Remaining Live BCG Organisms in Vaccinated Mice on the Maintenance of Immunity to Tuberculosis , 2004, Scandinavian journal of immunology.

[20]  J. Dahlerup,et al.  The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures , 2003 .

[21]  J. Gómez-Reino,et al.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. , 2003, Arthritis and rheumatism.

[22]  H. Thomas,et al.  Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus , 2002, The Journal of Immunology.

[23]  E. Keystone,et al.  The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[24]  R. Döffinger,et al.  Human interferon‐g‐mediated immunity is a genetically controlled continuous trait that determines the outcome of mycobacterial invasion , 2000, Immunological reviews.

[25]  J. Drijfhout,et al.  Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. , 2000, Protein expression and purification.

[26]  J. Dahlerup,et al.  The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. , 2003, Cytokine.